Investors interested in Medical - Dental Supplies stocks are likely familiar with Dentsply International (XRAY - Free Report) and Conmed (CNMD - Free Report) . But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look.
There are plenty of strategies for discovering value stocks, but we have found that pairing a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system produces the best returns. The Zacks Rank favors stocks with strong earnings estimate revision trends, and our Style Scores highlight companies with specific traits.
Currently, Dentsply International has a Zacks Rank of #2 (Buy), while Conmed has a Zacks Rank of #3 (Hold). The Zacks Rank favors stocks that have recently seen positive revisions to their earnings estimates, so investors should rest assured that XRAY has an improving earnings outlook. But this is just one piece of the puzzle for value investors.
Value investors also tend to look at a number of traditional, tried-and-true figures to help them find stocks that they believe are undervalued at their current share price levels.
Our Value category highlights undervalued companies by looking at a variety of key metrics, including the popular P/E ratio, as well as the P/S ratio, earnings yield, cash flow per share, and a variety of other fundamentals that have been used by value investors for years.
XRAY currently has a forward P/E ratio of 20.23, while CNMD has a forward P/E of 32.55. We also note that XRAY has a PEG ratio of 1.72. This popular figure is similar to the widely-used P/E ratio, but the PEG ratio also considers a company's expected EPS growth rate. CNMD currently has a PEG ratio of 2.18.
Another notable valuation metric for XRAY is its P/B ratio of 2.42. The P/B ratio is used to compare a stock's market value with its book value, which is defined as total assets minus total liabilities. For comparison, CNMD has a P/B of 4.09.
These metrics, and several others, help XRAY earn a Value grade of B, while CNMD has been given a Value grade of C.
XRAY sticks out from CNMD in both our Zacks Rank and Style Scores models, so value investors will likely feel that XRAY is the better option right now.